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Osteoarthritis is a major cause of incapaci-ty and economic loss in animals andpeople. While there are multiple drugs
available to alleviate the pain to some degree,
the goal of researchers is to find ways to control
the progression of the disease in affected joints.
There is little doubt that osteoarthritis (OA)
is a consequence of both mechanical and bio-
logical events. The defining event in OA is gen-
erally agreed to be the physical deterioration of
articular cartilage. Normal function of a joint
demands normal articular cartilage and articu-
lar cartilage is not capable of healing when it is
structurally damaged. Thus the major goal of
treatment and prevention of OA is preserva-
tion of articular cartilage. This goal demands a
detailed knowledge of the events involved in
degradation of articular cartilage matrix and
modern molecular techniques have enormous-
ly expanded understanding of these pathways.
Both degradation and synthesis of articular
cartilage involve a complex interaction of
cytokines, growth factors, receptors, receptor
antagonists and other peptides that affect the
highly specific components of cartilage matrix.
All of these elements are gene products and as
such there is obviously interest in both control-
ling and producing them by gene therapy. Gene
therapy for arthritis has many attractive poten-
tial advantages.
Many of the factors controlling cartilage
synthesis and degradation have potent, and
often undesirable, effects in many different tis-
sues, making their systemic use impossible.
Local delivery by gene therapy might result in
desirable local effects. Most of these active pep-
tides have very short half-lives precluding effec-
tive tissue concentrations by conventional
administration methods. Recombinant proteins
manufactured and purified in bulk for pharma-
ceutical use are extraordinarily expensive and
generally impractical for prolonged use. The
concept of gene therapy is to make the cells
residing within the joint serve as “local produc-
ers” for a desired (therapeutic) gene product.
Dr. Dean Richardson, professor and chief of
surgery at New Bolton Center, is investigating
gene therapy as a treatment to slow the disease
progression. He is working with horses because
they, like humans, commonly suffer from trau-
matic arthritis. A horse’s joints are quite large,
allowing for multiple biopsies, evaluation of
joint fluid, and observation by arthroscopy.
Richardson and his colleagues investigated
the use if a retroviral vector to deliver marker
genes into cultured synovial cells followed by
transfer of those multiplied cells from tissue
culture back into the horse. They found that
the transfer worked and the engrafted cells
with the marker genes expressed in the synovial
lining for up to five weeks and the cells
remained viable for at least six weeks.
In the second phase of the study the marker
genes were replaced by potentially therapeutic
genes for the interleukin 1 receptor antagonist
(EcIL1Ra), a protein that specifically blocks the
activity of interleukin 1, a cytokine that is one
of the most important mediators of arthritic
damage. It was found that the level of trans-
ferred gene product was not high enough to be
truly therapeutic. Retroviral vectors are cum-
bersome and expensive to develop, therefore
the group looked for another gene delivery
method.
In the continuation of the study an adeno-
associated viral vector (AAV) was used. This
vector holds many advantages including its
safety, an ability to infect non-dividing cells and
stably integrate its genetic material. It can there-
fore potentially be used for direct injection. The
researchers constructed an AAV into which they
inserted a marker gene coding for green fluores-
cent protein (GFP). These markers can be read-
ily identified in fresh or cultured tissue.
The study demonstrated that the AAV-GFP
safely infected the synovial lining and the
superficial layer of intact articular cartilage and
that the transferred genes were functional. The
expression of the transferred genes persisted
for at least six to nine weeks. It appears that
delivery of genes to cells employing AAV is
vastly more efficient than using a retroviral
vector. There were no signs of inflammation or
lameness in the horses injected with the AAV-
GFP construct, even in those horses receiving
multiple injections.
According to Dr. Richardson, this is the first
time that it has been shown that AAV-mediated
gene transfer to articular cartilage in vivo is fea-
sible. The group is constructing an AAV-EcILRa
to deliver therapeutic genes to the joints and
will tests its efficacy in the near future. The
group is also working on a second therapeutic
gene construct that may be valuable in inhibit-
ing inflammatory activity in a joint as well as
one containing a growth factor to help stimu-
late cartilage matrix production.
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New VHUP Kitchen
VHUP’s wards – 20 years old – are being
renovated and reconfigured to enable clinicians
and staff to provide even better care to the
patients. As part of the renovation, a modern
and more efficient kitchen was installed. The
suite includes an office for Charlotte Higgins,
nutrition nurse, and storage space for many of
the special diet foods needed at VHUP. The
reconfiguration and renovation of the kitchen
space was made possible though the generosity
of Hill’s Pet Nutrition, Inc.
Dr. Kathy Michel, assistant professor of nutrition,
shows some of the kitchen’s features to Harcha of
Hill’s.
Dr. Michelle Harcha of Hill’s Pet Nutrition, Inc. and
Dr. Gail Smith, chair, Department of Clinical
Studies, Philadelphia, cut the ribbon to the new
kitchen.
Charlotte Higgins, nutrition nurse, in her office
adjacent to the kitchen.
